Deals
Shire Buys ViroPharma for $4.2 Billion to Add Orphan Drug
This article is for subscribers only.
Shire Plc agreed to buy ViroPharma Inc. for about $4.2 billion to gain treatments for rare diseases and ease dependence on its best-selling Vyvanse pill for attention deficit hyperactivity disorder.
Shire will pay $50 a share in cash, 27 percent more than the closing price of ViroPharma on Nov. 8, the Dublin-based drugmaker said today in a statement.